Researchers found data that showed costs were reduced while tapering treatment with biologic disease-modifying antirheumatic drug therapies in patients with rheumatoid arthritis, but with a decrease in quality-adjusted life years.
Researchers interviewed rheumatologists in England to determine what factors they use to determine treatment in rheumatoid arthritis.
Investigators found data to determine subgroups of patients with rheumatoid arthritis, namely patients with DAS28 and pain flares, which they believe will help guide treatment.
In patients with rheumatoid arthritis, serum levels of reactive oxygen metabolites during treatment with tocilizumab are indicative of future clinical remission.
Investigators found data that showed that the documentation of a treat-to-target approach in rheumatoid arthritis was improved by a learning collaborative intervention with participation by rheumatologists and their patients.